Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOAH: Intraventricular NK Cells for Recurrent Posterior Fossa Tumors
NCT02271711Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2015
- Primary completion
- Aug 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous natural killer cells in medulloblastoma, ependymoma and Atypical teratoid rhabdoid tumor (ATRT), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Mar 2015; status: completed.
02
Drugs
autologous natural killer cells
03
Conditions
medulloblastomaependymomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT02271711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271711.